# A novel analysis of hemophilia treatment administration on patient utility: Combining a discrete choice experiment (DCE) with time trade-off (TTO) estimation

Benton M<sup>1,6</sup>, Hong D<sup>6</sup>, Skinner MW<sup>2,3</sup>, Garrison LP<sup>4</sup>, Karimi M<sup>5</sup>, Chen E<sup>5</sup>, Mead H<sup>5</sup>, Shi L<sup>6</sup>

¹Tulane University School of Medicine, New Orleans LA, USA; ²Institute for Policy Advancement Ltd., Washington, DC; ³McMaster University, Hamilton, Ontario; ⁴Univ of Washington, The CHOICE Institute, Department of Pharmacy, Seattle, WA; ⁵BioMarin Pharmaceutical Inc, Novato, CA; ⁶Tulane University School of Public Health & Tropical Medicine, New Orleans, LA

Adult patients\* (n=119)

### Introduction

- Hemophilia A (HA) is a bleeding disorder characterized by factor
   VIII (FVIII) deficiency
- HA treatments differ in administration and outcomes
- This study aimed to elicit preferences of adult males (≥18 years)
  with HA and quantify the incremental impact of treatment attribute
  changes on health utility with DCE-TTO methodology
- This final study (n=119) updates earlier pilot study, (n=25)
   (Benton M 2023. 115 participants completed DCE-TTO, and 119 completed both DCE-TTO and EQ-5D)

## Methods

- HA patients (aged ≥18y) were recruited from the Louisiana Center for Bleeding and Clotting Disorders at Tulane University and the National Hemophilia Foundation (NHF), the largest hemophilia patient advocacy organization in the USA, to participate in a web or in-clinic survey (Table 5)
- The DCE-TTO survey was developed based on the core outcome set for hemophilia gene therapy (coreHEM) (Table 1)
- Patients completed a DCE-TTO instrument with 20 randomly generated hypothetical choice sets to choose their preferred treatment (Table 1)
- Treatment characteristics were analyzed with TTO of 10, 15 and 20 years using conditional logistic models
- Socio-demographic data and clinical characteristics, were obtained from medical records or self-reports (Table 2)

### Results

- The coreHEM attributes were all statistically significant, and are important for patients with HA, with treatment and mental health being the most important (Figure 1)
- 119 HA patients completed the survey (mean age 37y, range 18-70y; 50% with moderate hemophilia A). Heterogenous demographic and clinical characteristics are described in (Table 2)
- 56% reported their current treatment was moderately burdensome (Table 3) (40% treated once every 4 weeks)
- When a TTO component was added (Table 4):
- Compared with a one-time IV treatment with 10-year or 5-year durability, treatment with multiple IV infusions weekly was associated with an annualized utility decrement (0.046 vs. 10-year durability and 0.044 vs. 5-year durability)
- Treatment with multiple SQ injections monthly was also associated with an annualized utility decrement (0.037 vs. 10-year durability and 0.030 vs. 5-year durability)

#### References

**1.** Benton M et al., (2023). POSTER ABSTRACTS. Haemophilia, 29: 24-202. https://doi.org/10.1111/hae.14715. EAHAD. Poster PO070. **2.** Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. (2018). Haemophilia., 24(4), e167–e172.


Table 2: Demographic and clinical characteristics of respondents (n=119)

Characteristic

Race, Ethnicity n (%)  White Black Asian 3 (3) Other, Prefer Not to Answer Hispanic or Latino/a Non-Hispanic or Latino/a Prefer Not to Answer Health insurance, n (%) Private! Asian 3 (3) Health insurance, n (%) Private! Asian Bear of the Status, n (%) Private! Public!  Employment status, n (%) Full-time/Part-time 101 (85) Long Term Sick/Disability, Unemployed, Retired Full-Time/Part-time Student Annual Income, n (%) SUSD 25,000 101 (85) Education level, n (%) High school or lesse 15 (12) 34y, 4y college or others* 104 (87) Disease severity, n (%) Mild/moderate Severe 39 (33) ABR, n (%) No bleeds* 13 (11) 1 to 4 bleeds 5 5 bleeds 124 (20) FVIII inhibitors in the past, n (%) Current treatment (at time of consent), n (%) Short-acting FVIII Con-demand Prophylaxist* 73 (61) Type of treatment (at time of consent), n (%) Short-acting FVIII Con-acting	Age, years, Mean (SD)	37 (10.06)
Black Asian 3 (3) Other, Prefer Not to Answer 2 (2) Hispanic or Latino/a Non-Hispanic or Latino/a Prefer Not to Answer Health insurance, n (%) Private! Bmployment status, n (%)" Full-time/Part-time Long Term Sick/Disability, Unemployed, Retired Full-time/Part-time Student Long Term Sick/Disability, Unemployed, Retired Full-time/Part-time Student Full-time/Part-time Full-time Ful	Race, Ethnicity n (%)	
Asian Other, Prefer Not to Answer Hispanic or Latino/a Non-Hispanic or Latino/a Non-Hispanic or Latino/a Prefer Not to Answer 3 (3)  Health insurance, n (%) Private' Public' Employment status, n (%)~ Full-time/Part-time Long Term Sick/Disability, Unemployed, Retired Full-Time/Part-time Student Full-Time/Part-time Student Full-Time/Part-time Student Full-Time/Part-time Student Full-Time/Part-time Student Annual Income, n (%) <susd (%)="" (12)="" (15)="" (185)="" 10="" 15="" 18="" 25,000°="" education="" high="" less*="" level,="" n="" or="" school="" susd="">∀y, 4y college or others* 10 (487)  Disease severity, n (%) Mild/moderate Severe 39 (33)  ABR, n (%) No bleeds* 13 (11) 1 to 4 bleeds 22 (69) &gt; 5 bleeds 24 (20)  FVIII inhibitors in the past, n (%) Current treatment (at time of consent), n (%) On-demand Prophylaxis= Type of treatment (at time of consent), n (%) Short-acting FVIII Cong-acting FVIII Cothers™ 99 (83)  Frequency of Treatment, n (%) ≥ than once a week (2,3,4 times a week) Once every 2-4 weeks &lt; 19 (66) &lt; than 4 weeks (once every 5 or 6 weeks)* 12 (10 Previous/Current Joint Procedure Previous/Current Joint Procedure 21 (18) Previous/Current Joint Procedure 21 (18) Previous/Current Joint Procedure Previous/Current Joint Procedure Frevious/Current Joint Procedure Previous/Current Joint Procedure Previous/Current Joint Procedure Frevious/Current Joint Procedure Previous/Current Joint Procedure Previous/Current Joint Procedure Previous/Current Joint Problems 67 (56) History of Hey Batt 4 weeks, n (%) Very good to Excellent Fair to Good Fair to</susd>	White	
Other, Prefer Not to Answer  Hispanic or Latino/a  Non-Hispanic or Latino/a  Prefer Not to Answer  3 (3)  Health insurance, n (%) Private¹ Public¹  Employment status, n (%)~  Full-time/Part-time  Long Term Sick/Disability, Unemployed, Retired Full-Time/Part-time Student  Annual Income, n (%)  <\$USD 25,000* 18 (15) \$USD 25,000* 101 (85)  Education level, n (%)  High school or less³ 14 (12)  34y, 4y college or others³  No bleeds³  No bleeds³  13 (11) 1 to 4 bleeds 2 (69)  VIII Inhibitors in the past, n (%)  Current treatment (at time of consent), n (%)  On-demand Prophylaxis¹ Type of treatment (at time of consent), n (%)  Short-acting FVIII  Long-acting FVIII  Cothers¹¹  Prequency of Treatment, n (%)  ≥ than once a week (2,3,4 times a week) Once every 2-4 weeks < than 4 weeks (once every 5 or 8 weeks)³  Previous/current Joint Problems  Previous/Current Joint Problems  67 (56)  History of HIV  8 (7)  History of Hepatitis C  General health over the past 4 weeks, n (%) Very good to Excellent Service  3 (22)  1 (11)  Cotheral health over the past 4 weeks, n (%) Very good to Excellent Service Servic		
Hispanic or Latino/a Non-Hispanic or Latino/a Prefer Not to Answer  Realth insurance, n (%) Private!		
Non-Hispanic or Latino/a   20 (34)   Prefer Not to Answer   3 (3)		
Prefer Not to Answer   3 (3)     Health insurance, n (%)     Private   33 (28)     Public   86 (72)     Employment status, n (%)     Full-time/Part-time   101 (85)     Long Term Sick/Disability, Unemployed, Retired   16 (13)     Full-time/Part-time Student   6 (5)     Annual Income, n (%)     < \$USD 25,000   18 (15)     \$VSD 25,000   101 (85)     Education level, n (%)     High school or less   15 (12)     >4y, 4y college or others   104 (87)     Disease severity, n (%)     Mild/moderate   80 (67)     Severe   39 (33)     ABR, n (%)     No bleeds   13 (11)     1 to 4 bleeds   82 (69)     > 5 bleeds   24 (20)     FVIII inhibitors in the past, n (%)     Current treatment (at time of consent), n (%)     On-demand   46 (39)     Prophylaxis   73 (61)     Type of treatment (at time of consent), n (%)     Short-acting FVIII   2 (2)     Long-acting FVIII   18 (15)     Others   99 (83)     Frequency of Treatment, n (%)   28 (24)     ≥ than once a week (2,3,4 times a week)     Once every 2-4 weeks   79 (66)     < than 4 weeks (once every 5 or 6 weeks)   12 (10     Previous/Current use of central device, n (%)   13 (11)     Previous/Current Joint Procedure   21 (18)     Previous/Current Joint Procedure   21 (18)     Previous/Current Joint Problems   67 (56)     History of Hepatitis C   17 (14)     General health over the past 4 weeks, n (%)     Very good to Excellent   30 (25)     Fair to Good   88 (74)     Poor   1 (11)		
Health insurance, n (%) Private¹ Public¹ Private¹ Public¹ Public¹ Employment status, n (%)⁻ Full-time/Part-time Long Term Sick/Disability, Unemployed, Retired Full-Time/Part-time Student Annual Income, n (%) ⟨\$USD 25,000⁰ ⟨\$USD 25,000⁰  SUSD 25,000  Long Term Sick/Disability, Unemployed, Retired Full-Time/Part-time Student Annual Income, n (%) ⟨\$USD 25,000⁰  S\$USD 25,000  Long Term Sick/Disability, Unemployed, Retired Full-Time/Part-time Student Annual Income, n (%) ⟨\$USD 25,000⁰  Long Term Sick/Disability, Unemployed, Retired Full Status  Education level, n (%)  High school or less⁴  Long Ag, y college or others⁴  Severe  Long Ag, y college or others⁴  Long Ag, y college or others⁴  Type of the status  Long Ag, y college or others⁴  Type of treatment (at time of consent), n (%)  Short-acting FVIII  Long-acting FVIII		
Private¹		<u>0 (0)</u>
Public¹		33 (28)
Employment status, n (%)" Full-time/Part-time Long Term Sick/Disability, Unemployed, Retired Full-Time/Part-time Student Annual Income, n (%)  <\$\\$USD 25,000\times 18 (15)  >\$\\$USD 25,000\times 19 101 (85)  Education level, n (%) High school or less\times 15 (12)  >4y, 4y college or others\times 104 (87)  Disease severity, n (%) Mild/moderate Severe 39 (33)  ABR, n (%) No bleeds\times 13 (11) 1 to 4 bleeds > 5 bleeds  14 (20)  FVIII inhibitors in the past, n (%) Current treatment (at time of consent), n (%) On-demand Prophylaxis\times 73 (61)  Type of treatment (at time of consent), n (%)\times 58 (24) Short-acting FVIII Long-acting FVIII Others\times 99 (83)  Frequency of Treatment, n (%) ≥ than once a week (2,3,4 times a week) Once every 2-4 weeks < 19 (66) < than 4 weeks (once every 5 or 6 weeks) 12 (10  Previous/Current Joint Problems Frequency does also the past 4 weeks, n (%) Very good to Excellent Filt to Good Poor  1 (1)		
Full-time/Part-time Long Term Sick/Disability, Unemployed, Retired Full-Time/Part-time Student Annual Income, n (%)  <\$USD 25,000  \$USD 25,000  \$US		
Long Term Sick/Disability, Unemployed, Retired Full-Time/Part-time Student Annual Income, n (%)  <\$USD 25,000³  \$USD 25,000³  \$USD 25,000\$  It (85)  Education level, n (%) High school or less³  45 (12)  >4y, 4y college or others³  Disease severity, n (%) Mild/moderate  Severe  39 (33)  ABR, n (%) No bleeds³  13 (11) 1 to 4 bleeds  5 bleeds  Very limit in the past, n (%)  Current treatment (at time of consent), n (%) On-demand Prophylaxis³  Type of treatment (at time of consent), n (%) Short-acting FVIII Long-acting FVIII Cothers™  Frequency of Treatment, n (%)  ≥ than once a week (2,3,4 times a week) Once every 2-4 weeks  < than 4 weeks (once every 5 or 6 weeks)°  12 (10 Previous/Current Joint Procedure  21 (18) Previous/Current Joint Procedure  21 (18) Previous of HIV History of HIV History of HIV History of Hepatitis C General health over the past 4 weeks, n (%) Very good to Excellent Fair to Good Poor  1 (1)		101 (85)
Full-Time/Part-time Student  Annual Income, n (%)  <\$USD 25,000°  \$USD 25,000°  High school or less°  24y, 4y college or others°  Disease severity, n (%)  Mild/moderate  Severe  39 (33)  ABR, n (%)  No bleeds°  15 (12)  104 (87)  Disease severity, n (%)  Mild/moderate  Severe  39 (33)  ABR, n (%)  No bleeds°  13 (11)  1 to 4 bleeds  5 bleeds  13 (11)  1 to 4 bleeds  5 bleeds  13 (10)  Current treatment (at time of consent), n (%)  On-demand  Prophylaxis <sup>‡‡</sup> Type of treatment (at time of consent), n (%)  Short-acting FVIII  Long-acting FVIII  Cothers™  99 (83)  Frequency of Treatment, n (%)  ≥ than once a week (2,3,4 times a week)  Once every 2-4 weeks  < than 4 weeks (once every 5 or 6 weeks)°  12 (10)  Previous/current Joint Procedure  Previous/Current Joint Problems  67 (56)  History of HIV  History of Hepatitis C  General health over the past 4 weeks, n (%)  Very good to Excellent Fair to Good Poor  1 (1)	Long Term Sick/Disability, Unemployed, Retired	
<§USD 25,000		6 (5)
>\$USD 25,000  Education level, n (%) High school or less*	Annual Income, n (%)	
Education level, n (%) High school or less <sup>8</sup> >4y, 4y college or others*  Disease severity, n (%) Mild/moderate Severe 39 (33)  ABR, n (%) No bleeds* 1 to 4 bleeds 5 bleeds  FVIII inhibitors in the past, n (%) On-demand Prophylaxis*  Type of treatment (at time of consent), n (%) Short-acting FVIII Long-acting FVIII Others™  Path an once a week (2,3,4 times a week) Once every 2-4 weeks < than 4 weeks (once every 5 or 6 weeks)*  Trevious/Current Joint Procedure Previous/Current Joint Problems History of HIV History of Hepatitis C General health over the past 4 weeks, n (%) Very good to Excellent Fair to Good Poor  1 1 (1)	<\$USD 25,000°	18 (15)
High school or less <sup>§</sup> 15 (12)	>\$USD 25,000	101 (85)
>4y, 4y college or others* 104 (87)  Disease severity, n (%)  Mild/moderate 80 (67) Severe 39 (33)  ABR, n (%)  No bleeds* 13 (11) 1 to 4 bleeds 82 (69) > 5 bleeds 24 (20)  FVIII inhibitors in the past, n (%)  Current treatment (at time of consent), n (%)  On-demand 46 (39) Prophylaxis‡ 73 (61)  Type of treatment (at time of consent), n (%)**  Short-acting FVIII 2 (2)  Long-acting FVIII 18 (15) Others™ 99 (83)  Frequency of Treatment, n (%) 28 (24) ≥ than once a week (2,3,4 times a week) Once every 2-4 weeks 79 (66) < than 4 weeks (once every 5 or 6 weeks)*  Trevious/current use of central device, n (%)  Previous/Current Joint Problems 67 (56) History of HIV 8 (7) History of Hepatitis C 17 (14)  General health over the past 4 weeks, n (%) Very good to Excellent 30 (25) Fair to Good 88 (74) Poor 1 (11)	Education level, n (%)	
Disease severity, n (%)  Mild/moderate Severe 39 (33)  ABR, n (%)  No bleeds <sup>b</sup> 13 (11) 1 to 4 bleeds 24 (20)  FVIII inhibitors in the past, n (%)  Current treatment (at time of consent), n (%)  On-demand Prophylaxis <sup>‡‡</sup> 73 (61)  Type of treatment (at time of consent), n (%)  Short-acting FVIII Long-acting FVIII Long-acting FVIII Others <sup>¶</sup> 99 (83)  Frequency of Treatment, n (%) ≥ than once a week (2,3,4 times a week) Once every 2-4 weeks <		
Mild/moderate Severe  Severe  39 (33)  ABR, n (%) No bleedsb 13 (11) 1 to 4 bleeds 82 (69) > 5 bleeds 24 (20)  FVIII inhibitors in the past, n (%)  Current treatment (at time of consent), n (%) On-demand 46 (39) Prophylaxistt 73 (61)  Type of treatment (at time of consent), n (%) Short-acting FVIII 2 (2) Long-acting FVIII 18 (15) Otherstt 99 (83)  Frequency of Treatment, n (%) 28 (24) ≥ than once a week (2,3,4 times a week) Once every 2-4 weeks 79 (66) < than 4 weeks (once every 5 or 6 weeks)c 12 (10  Previous/current use of central device, n (%) 13 (11) Previous/Current Joint Procedure 21 (18) Previous/Current Joint Problems 67 (56) History of HIV 8 (7) History of Hepatitis C  General health over the past 4 weeks, n (%) Very good to Excellent 30 (25) Fair to Good 88 (74) Poor 1 (11)		104 (87)
Severe       39 (33)         ABR, n (%)       13 (11)         No bleedsb       13 (11)         1 to 4 bleeds       82 (69)         > 5 bleeds       24 (20)         FVIII inhibitors in the past, n (%)       82 (69)         Current treatment (at time of consent), n (%)       46 (39)         On-demand       46 (39)         Prophylaxis <sup>±‡</sup> 73 (61)         Type of treatment (at time of consent), n (%) <sup>SS</sup> Short-acting FVIII         Long-acting FVIII       2 (2)         Long-acting FVIII       18 (15)         Otherstown       99 (83)         Frequency of Treatment, n (%)       28 (24)         ≥ than once a week (2,3,4 times a week)       79 (66)         < than 4 weeks (once every 5 or 6 weeks) <sup>c</sup> 12 (10         Previous/current use of central device, n (%)       13 (11)         Previous/Current Joint Procedure       21 (18)         Previous/Current Joint Problems       67 (56)         History of HIV       8 (7)         History of Hepatitis C       17 (14)         General health over the past 4 weeks, n (%)       Very good to Excellent       30 (25)         Fair to Good       88 (74)         Poor       1 (1)		00 (07)
ABR, n (%)  No bleeds <sup>b</sup> 13 (11)  1 to 4 bleeds  5 bleeds  24 (20)  FVIII inhibitors in the past, n (%)  Current treatment (at time of consent), n (%)  On-demand  Prophylaxis <sup>‡‡</sup> 73 (61)  Type of treatment (at time of consent), n (%) <sup>§§</sup> Short-acting FVIII  Long-acting FVIII  Others <sup>¶¶</sup> 18 (15)  Once every 2-4 weeks  ✓ than once a week (2,3,4 times a week)  Once every 2-4 weeks  ✓ than 4 weeks (once every 5 or 6 weeks) <sup>c</sup> Previous/Current Joint Procedure  Previous/Current Joint Problems  History of HIV  History of Hepatitis C  General health over the past 4 weeks, n (%)  Very good to Excellent  Fair to Good  Poor  13 (11)  13 (11)  14 (11)  15 (11)  16 (11)  17 (14)  18 (7)  19 (25)  17 (14)  18 (7)  19 (25)  19 (25)  10 (25)  10 (25)  11 (11)		
No bleeds <sup>b</sup> 13 (11)         1 to 4 bleeds       82 (69)         > 5 bleeds       24 (20)         FVIII inhibitors in the past, n (%)       82 (69)         Current treatment (at time of consent), n (%)       46 (39)         On-demand       46 (39)         Prophylaxis <sup>‡‡</sup> 73 (61)         Type of treatment (at time of consent), n (%) <sup>§§</sup> 2 (2)         Short-acting FVIII       2 (2)         Long-acting FVIII       18 (15)         Others <sup>¶¶</sup> 99 (83)         Frequency of Treatment, n (%)       28 (24)         ≥ than once a week (2,3,4 times a week)       79 (66)         < than 4 weeks (once every 5 or 6 weeks) <sup>o</sup> 12 (10         Previous/current use of central device, n (%)       13 (11)         Previous/Current Joint Procedure       21 (18)         Previous/Current Joint Problems       67 (56)         History of HIV       8 (7)         History of Hepatitis C       17 (14)         General health over the past 4 weeks, n (%)       Very good to Excellent       30 (25)         Fair to Good       88 (74)         Poor       1 (1)		39 (33)
1 to 4 bleeds		13 (11)
> 5 bleeds 24 (20)  FVIII inhibitors in the past, n (%) 82 (69)  Current treatment (at time of consent), n (%) On-demand 46 (39) Prophylaxis <sup>‡‡</sup> 73 (61)  Type of treatment (at time of consent), n (%) <sup>§§</sup> Short-acting FVIII 2 (2) Long-acting FVIII 18 (15) Others <sup>™</sup> 99 (83)  Frequency of Treatment, n (%) 28 (24) ≥ than once a week (2,3,4 times a week) Once every 2-4 weeks 79 (66) < than 4 weeks (once every 5 or 6 weeks) <sup>c</sup> 12 (10  Previous/current use of central device, n (%) 13 (11)  Previous/Current Joint Procedure 21 (18)  Previous/Current Joint Problems 67 (56)  History of HIV 8 (7)  History of Hepatitis C 17 (14)  General health over the past 4 weeks, n (%) Very good to Excellent 30 (25) Fair to Good 88 (74) Poor 1 (1)		
FVIII inhibitors in the past, n (%)  Current treatment (at time of consent), n (%)  On-demand  Prophylaxis <sup>‡‡</sup> 73 (61)  Type of treatment (at time of consent), n (%)  Short-acting FVIII  Long-acting FVIII  Long-acting FVIII  Others <sup>¶1</sup> Prequency of Treatment, n (%)  ≥ than once a week (2,3,4 times a week)  Once every 2-4 weeks  < than 4 weeks (once every 5 or 6 weeks) <sup>c</sup> Than 4 weeks (once every 5 or 6 weeks) <sup>c</sup> Than 4 weeks (once every 5 or 6 weeks) <sup>c</sup> Previous/current use of central device, n (%)  Previous/Current Joint Procedure  Previous/Current Joint Problems  67 (56)  History of HIV  Refreshed  8 (7)  History of Hepatitis C  General health over the past 4 weeks, n (%)  Very good to Excellent  Fair to Good  Poor  1 (1)		
Current treatment (at time of consent), n (%) On-demand Prophylaxis <sup>‡‡</sup> 73 (61)  Type of treatment (at time of consent), n (%) Short-acting FVIII Long-acting FVIII 18 (15) Others <sup>¶¶</sup> 99 (83)  Frequency of Treatment, n (%) ≥ than once a week (2,3,4 times a week) Once every 2-4 weeks < than 4 weeks (once every 5 or 6 weeks) < than 4 weeks (once every 5 or 6 weeks)  Previous/current use of central device, n (%) 13 (11)  Previous/Current Joint Procedure 21 (18)  Previous/Current Joint Problems 67 (56)  History of HIV 8 (7)  History of Hepatitis C General health over the past 4 weeks, n (%) Very good to Excellent Fair to Good Fair to Good Fair to Good For the past 4 weeks, n (%) Poor 1 (1)		
On-demand       46 (39)         Prophylaxis <sup>‡‡</sup> 73 (61)         Type of treatment (at time of consent), n (%) <sup>§§</sup> 2 (2)         Short-acting FVIII       18 (15)         Others <sup>™</sup> 99 (83)         Frequency of Treatment, n (%)       28 (24)         ≥ than once a week (2,3,4 times a week)       79 (66)         Once every 2-4 weeks       79 (66)         < than 4 weeks (once every 5 or 6 weeks) <sup>c</sup> 12 (10         Previous/current use of central device, n (%)       13 (11)         Previous/Current Joint Procedure       21 (18)         Previous/Current Joint Problems       67 (56)         History of HIV       8 (7)         History of Hepatitis C       17 (14)         General health over the past 4 weeks, n (%)       30 (25)         Fair to Good       88 (74)         Poor       1 (1)		02 (00)
Prophylaxis#       73 (61)         Type of treatment (at time of consent), n (%)\$\$       2 (2)         Short-acting FVIII       2 (2)         Long-acting FVIII       18 (15)         Others™       99 (83)         Frequency of Treatment, n (%)       28 (24)         ≥ than once a week (2,3,4 times a week)       79 (66)         < than 4 weeks (once every 5 or 6 weeks)°		46 (39)
Short-acting FVIII       2 (2)         Long-acting FVIII       18 (15)         Others™       99 (83)         Frequency of Treatment, n (%)       28 (24)         ≥ than once a week (2,3,4 times a week)       79 (66)         < than 4 weeks (once every 5 or 6 weeks)°		
Long-acting FVIII Others Others 199 (83)  Frequency of Treatment, n (%) ≥ than once a week (2,3,4 times a week) Once every 2-4 weeks <	Type of treatment (at time of consent), n (%)§§	
Others  Frequency of Treatment, n (%)  ≥ than once a week (2,3,4 times a week)  Once every 2-4 weeks  < than 4 weeks (once every 5 or 6 weeks)  Previous/current use of central device, n (%)  Previous/Current Joint Procedure  Previous/Current Joint Problems  67 (56)  History of HIV  Reneral health over the past 4 weeks, n (%)  Very good to Excellent  Fair to Good  Poor  99 (83)  28 (24)  29 (66)  79 (66)  12 (10  13 (11)  8 (71)  13 (11)  7 (14)  8 (7)  17 (14)  8 (7)  17 (14)  18 (25)  19 (25)  19 (25)  10 (25)  11 (1)	Short-acting FVIII	2 (2)
Frequency of Treatment, n (%)  ≥ than once a week (2,3,4 times a week)  Once every 2-4 weeks  79 (66) < than 4 weeks (once every 5 or 6 weeks)° 12 (10 Previous/current use of central device, n (%) 13 (11) Previous/Current Joint Procedure 21 (18) Previous/Current Joint Problems 67 (56) History of HIV 8 (7) History of Hepatitis C 17 (14) General health over the past 4 weeks, n (%) Very good to Excellent 30 (25) Fair to Good Poor 1 (1)	Long-acting FVIII	18 (15)
≥ than once a week (2,3,4 times a week) Once every 2-4 weeks < than 4 weeks (once every 5 or 6 weeks)° Previous/current use of central device, n (%) 13 (11) Previous/Current Joint Procedure 21 (18) Previous/Current Joint Problems 67 (56) History of HIV 8 (7) History of Hepatitis C 17 (14)  General health over the past 4 weeks, n (%) Very good to Excellent Fair to Good Poor 1 (1)	Others	99 (83)
Once every 2-4 weeks <ul> <li>than 4 weeks (once every 5 or 6 weeks)°</li> <li>12 (10</li> </ul> <li>Previous/current use of central device, n (%) <ul> <li>13 (11)</li> <li>Previous/Current Joint Procedure</li> <li>21 (18)</li> </ul> </li> <li>Previous/Current Joint Problems</li> <li>67 (56)</li> <li>History of HIV</li> <li>8 (7)</li> <li>History of Hepatitis C</li> <li>17 (14)</li> <li>General health over the past 4 weeks, n (%) <ul> <li>Very good to Excellent</li> <li>Fair to Good</li> <li>Poor</li> <li>1 (1)</li> </ul></li>		28 (24)
< than 4 weeks (once every 5 or 6 weeks)° Previous/current use of central device, n (%) Previous/Current Joint Procedure 21 (18) Previous/Current Joint Problems 67 (56) History of HIV History of Hepatitis C 7 (14) General health over the past 4 weeks, n (%) Very good to Excellent Fair to Good 88 (74) Poor 12 (10 13 (11) 30 (25) 88 (74) 1 (1)	,	
Previous/current use of central device, n (%)  Previous/Current Joint Procedure  Previous/Current Joint Problems  67 (56)  History of HIV  Ristory of Hepatitis C  General health over the past 4 weeks, n (%)  Very good to Excellent  Fair to Good  Poor  13 (11)  21 (18)  8 (7)  17 (14)  8 (7)  17 (14)  18 (25)  88 (74)  19 (11)		
Previous/Current Joint Procedure 21 (18)  Previous/Current Joint Problems 67 (56)  History of HIV 8 (7)  History of Hepatitis C 17 (14)  General health over the past 4 weeks, n (%)  Very good to Excellent 30 (25)  Fair to Good 88 (74)  Poor 1 (1)		
Previous/Current Joint Problems 67 (56)  History of HIV 8 (7)  History of Hepatitis C 17 (14)  General health over the past 4 weeks, n (%)  Very good to Excellent 30 (25)  Fair to Good 88 (74)  Poor 1 (1)		
History of HIV  History of Hepatitis C  General health over the past 4 weeks, n (%)  Very good to Excellent  Fair to Good  Poor  S (7)  17 (14)  30 (25)  88 (74)  1 (1)		
History of Hepatitis C  General health over the past 4 weeks, n (%)  Very good to Excellent  Fair to Good  Poor  17 (14)  30 (25)  88 (74)  1 (1)		
General health over the past 4 weeks, n (%) Very good to Excellent Fair to Good Poor  1 (1)		
Very good to Excellent  Fair to Good  Poor  30 (25) 88 (74) 1 (1)	History of Hepatitis C	17 (14)
Fair to Good Poor 1 (1)		
Poor 1 (1)		

employer/group sponsored or individual commercial insurance plans; ¶Includes Medicare, Medicaid or other federal insurance; & includes prefer not to answer, #Includes 2-year, vocational or technical degrees; ‡†Those reporting no treatment/don't know; §§Respondents could report more than one; none not shown, ¶Includes bypassing agents, non-factor products (e.g. emicizumab), or none, ~Three patients are full-time students and work part-time, two patients work full-time and are full-time students, one patient works part-time and is retired. alncludes don't know/prefer not to answer, blncludes don't know, clncludes don't know.

Figure 1. Regression Coefficient\*-DCE on coreHEM attributes (n=115)



\*Patient preferences based on the magnitude of the regression coefficient, is statistically significant when comparing at least one level of that attribute with the reference level. †Regression coefficient < 0 shows aversion to a treatment attribute.

Table 1: Treatment characteristics and their levels considered in the DCE-TTO survey

Treat	ment characteristic	Levels
Treatment	Frequency and mode of treatment	<ul> <li>One-time IV infusion, works for 5yrs, followed by regular hemophilia treatment</li> <li>One-time IV infusion, works for 10yrs, followed by regular hemophilia treatment</li> <li>2-3 times IV infusion per week</li> <li>1-2 times SQ injection per month</li> </ul>
Mental health	Mental health status	<ul> <li>Always concerned your hemophilia</li> <li>Occasionally concerned about your hemophilia</li> <li>No concern about your hemophilia</li> </ul>
Chronic pain	Pain from a persistent cause	<ul><li>Yes</li><li>No</li></ul>
Bleeding	Number of bleeds per year	<ul><li>None</li><li>1-4 times</li><li>5 or more</li></ul>
Lifeduration	Remaining years of life	<ul><li>10 years</li><li>15 years</li><li>20 years</li></ul>

\*IV intravenous, \*\*SQ Subcutaneous

#### Acknowledgements

Hemophilia patients and their families, Tulane University School of Public Health and Tropical Medicine, The Louisiana Center for Bleeding and Clotting Disorders, Tulane University School of Medicine, McMaster University, Institute for Policy Advancement, University of Washington, BioMarin, National Hemophilia Foundation (NHF)

Table 3: Burden of hemophilia treatment

Characteristic	Adult patients (n=119) n (%)
No burden	13 (10.92%)
Slight burden	28 (23.53%)
Moderate burden	67 (56.30%)
Severe burden	11 (9.24%)

Table 4: DCE-TTO annualized utility decrement (n=115\*)

Characteristic	n=115	
10 yr Durability (multiple IV weekly infusions)	0.046	
5 yr Durability (multiple IV weekly infusions)	0.044	
10 yr Durability (multiple SQ monthly injections)	0.037	
5 yr Durability (multiple SQ monthly injections)	0.030	
*Note: 115 participants completed DCE-TTO, and 119 completed both DCE-TTO and EQ-5D.		

**Table 5: DCE-TTO survey example** 

Attribute	Treatment A	Treatment B
Treatment	2-3 IV infusions per week	1-2 times SQ injection Per Month
Mental health	Always concerned	Never concerned
Chronic Pain	Yes	No
Bleeding	None	1-4 times
Life Dduration	10 years	20 years

# Discussion

- DCE attributes leveraged the coreHEM framework for gene therapy,
   which was developed by a multi-stakeholder patient-led task force
- This combined use of DCE and TTO provides a new approach to measuring health utility of hemophilia treatment administration. Future studies should compare this approach with other approaches such as standard health utility measures, vignettebased utility measures, and differences in patient preferences among subgroups (e.g., by severity, by treatment type)
- The study sample was recruited from a single Hemophilia Treatment Center in Louisiana and NHF. We cannot generalize the results to other study settings
- This updated final study confirms the results from the pilot DCE-TTO study presented at EAHAD

### Conclusions

- A one-time IV treatment can improve the health utility over repeated prophylactic administration
- Durability of the one-time IV treatment impacts the incremental utility improvement; patients with hemophilia are willing to trade life years to reduce treatment burden
- Patients with hemophilia indicated that all coreHEM outcomes are important for treatment choices, but those of most importance are treatment characteristics and mental health





Presented at the AMCP Nexus 2023 Meeting, October 16–19 2023, Orlando, FL